• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeu ADR (NQ: SMMT )

    18.31 -1.14 (-5.86%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,145,538
    Open 19.45
    Bid (Size) 18.32 (1)
    Ask (Size) 18.42 (7)
    Prev. Close 19.45
    Today's Range 18.23 - 19.45
    52wk Range 1.840 - 33.89
    Shares Outstanding 97,381,774
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
    Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China. 
    Via Investor's Business Daily
    BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
    Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus. 
    Via Benzinga

    Performance

    YTD
    +593.56%
    +593.56%
    1 Month
    -21.95%
    -21.95%
    3 Month
    +57.84%
    +57.84%
    6 Month
    +312.39%
    +312.39%
    1 Year
    +884.41%
    +884.41%

    More News

    Read More
    MarketBeat Week in Review – 11/4 - 11/8
    Via MarketBeat
    Topics Economy Government
    Exposures Interest Rates Political
    2 Hot Biopharma Stocks to Buy and Hold for 5 Years
    Via The Motley Fool
    Why Summit Therapeutics Stock Was a Winner Today
    Via The Motley Fool
    Preview: Summit Therapeutics's Earnings
    Via Benzinga
    (SMMT) - Analyzing Summit Therapeutics's Short Interest
    Via Benzinga
    Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
    Via Benzinga
    Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
    Via MarketBeat
    Exposures Product Safety
    This Tencent Music Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
    Via Benzinga
    3 Magnificent Stocks Under $100 to Buy in November
    Via The Motley Fool
    2 Dividend Stocks to Buy for a Lifetime of Passive Income
    Via The Motley Fool
    3 Stocks That Have Generated 1,000% Returns in Just 2 Years
    Via The Motley Fool
    Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
    Via News Direct
    Is Summit Therapeutics a Millionaire Maker?
    Via The Motley Fool
    Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
    Via The Motley Fool
    Billionaire Bob Duggan Snags $33M Miami Penthouse Amid Summit Therapeutics 689% Stock Rally
    Via Benzinga
    Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
    Via The Motley Fool
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Up 700% This Year, Is It Too Late to Invest in This Stock?
    Via The Motley Fool
    Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
    Via The Motley Fool
    3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
    Via The Motley Fool
    2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.